Health
IMV Provides Updates On COVID-19 Vaccine Program – BioSpace
Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today provides updates on its vaccine candidate, DPX-COVID-19, for the prevention of infection caused by the novel coronavirus SARS-COV-2.
We are advancing DPX-COVID-19 on the strength of its novel mechanism of action and potential for rapid scale-up manufacturing. We greatly appreciate…
-
Noosa News12 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business14 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
General24 hours agoAn open letter to pro-Palestinian protesters
-
Noosa News13 hours agoBrisbane news live: 80,000 green bins rolled out | Residents told to prepare for ‘violent’ summer storms | Council declares water safe for swimming despite dead fish